Selection of AmpC β-Lactamase variants and Metallo-β-Lactamases leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam resistance during treatment of MDR/XDR Pseudomonas aeruginosa infections
| UDC.coleccion | Investigación | |
| UDC.departamento | Fisioterapia, Medicina e Ciencias Biomédicas | |
| UDC.grupoInv | Investigación en Microbiología (INIBIC) | |
| UDC.institutoCentro | INIBIC - Instituto de Investigacións Biomédicas de A Coruña | |
| UDC.issue | 2 | |
| UDC.journalTitle | Antimicrobial Agents and Chemotherapy | |
| UDC.startPage | e0206721 | |
| UDC.volume | 66 | |
| dc.contributor.author | Ruedas-López, Alba | |
| dc.contributor.author | Alonso-García, Isaac | |
| dc.contributor.author | Lasarte-Monterrubio, Cristina | |
| dc.contributor.author | Guijarro-Sánchez, Paula | |
| dc.contributor.author | Gato, Eva | |
| dc.contributor.author | Vázquez-Ucha, Juan Carlos | |
| dc.contributor.author | Vallejo, J. A. | |
| dc.contributor.author | Fraile-Ribot, Pablo Arturo | |
| dc.contributor.author | Fernández-Pérez, Begoña | |
| dc.contributor.author | Velasco, David | |
| dc.contributor.author | Gutiérrez-Urbón, José María | |
| dc.contributor.author | Oviaño, Marina | |
| dc.contributor.author | Beceiro Casas, Alejandro | |
| dc.contributor.author | González-Bello, Concepción | |
| dc.contributor.author | Oliver, Antonio | |
| dc.contributor.author | Arca-Suárez, Jorge | |
| dc.contributor.author | Bou, Germán | |
| dc.date.accessioned | 2025-11-07T10:31:21Z | |
| dc.date.available | 2025-11-07T10:31:21Z | |
| dc.date.issued | 2022-02-15 | |
| dc.description.abstract | [Abstract] Infections caused by ceftolozane-tazobactam and ceftazidime-avibactam-resistant P. aeruginosa infections are an emerging concern. We aimed to analyze the underlying ceftolozane-tazobactam and ceftazidime-avibactam resistance mechanisms in all multidrug-resistant or extensively drug-resistant (MDR/XDR) P. aeruginosa isolates recovered during 1 year (2020) from patients with a documented P. aeruginosa infection. Fifteen isolates showing ceftolozane-tazobactam and ceftazidime-avibactam resistance were evaluated. Clinical conditions, previous positive cultures, and β-lactams received in the previous month were reviewed for each patient. MICs were determined by broth microdilution. Multilocus sequence types (MLSTs) and resistance mechanisms were determined using short- and long-read whole-genome sequencing (WGS). The impact of Pseudomonas-derived cephalosporinases (PDCs) on β-lactam resistance was demonstrated by cloning into an ampC-deficient PAO1 derivative (PAOΔC) and construction of 3D models. Genetic support of acquired β-lactamases was determined in silico from high-quality hybrid assemblies. In most cases, the isolates were recovered after treatment with ceftolozane-tazobactam or ceftazidime-avibactam. Seven isolates from different sequence types (STs) owed their β-lactam resistance to chromosomal mutations and all displayed specific substitutions in PDC: Phe121Leu and Gly222Ser, Pro154Leu, Ala201Thr, Gly214Arg, ΔGly203-Glu219, and Glu219Lys. In the other eight isolates, the ST175 clone was overrepresented (6 isolates) and associated with IMP-28 and IMP-13, whereas two ST1284 isolates produced VIM-2. The cloned PDCs conferred enhanced cephalosporin resistance. The 3D PDC models revealed rearrangements affecting residues involved in cephalosporin hydrolysis. Carbapenemases were chromosomal (VIM-2) or plasmid-borne (IMP-28, IMP-13) and associated with class-1 integrons located in Tn402-like transposition modules. Our findings highlighted that cephalosporin/β-lactamase inhibitors are potential selectors of MDR/XDR P. aeruginosa strains producing PDC variants or metallo-β-lactamases. Judicious use of these agents is encouraged. | |
| dc.description.sponsorship | his work was supported by Projects and PI18/00501 to GB PI17/01482 and PI20/01212 awarded to AB, all within in the National Plan for Scientific Research, Development and Technological Innovation 2013 to 2016 and funded by the ISCIII – General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe”. The study was also funded by project IN607A 2020/05 (GAIN-Agencia Gallega de Innovación – Consellería de Economía, Emprego e Industria) awarded to GB and IN607D 2021/12 awarded to AB. This work was also supported by Planes Nacionales de I+D+i2008 to 2011/2013 to 2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectiosus Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth from 2014 to 2020. CGB acknowledges the financial support from the Spanish Ministry of Science and Innovation (PID2019-105512RB-I00), the Xunta de Galicia (ED431C 2021/29) and Centro singular de investigación de Galicia accreditation from 2019 to 2022 (ED431G 2019/03), and the European Regional Development Fund (ERDF). CLM was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and PGS was financially supported by IN607A 2020/05 Grant (Xunta de Galicia). JCVU was financially supported by the pFIS program (ISCIII, PI17/01482). M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006). JAS was financially supported by the Rio Hortega program (ISCIII-SERGAS, CM19/00219). | |
| dc.identifier.citation | Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha JC, Vallejo JA, Fraile-Ribot PA, Fernández-Pérez B, Velasco D, Gutiérrez-Urbón JM, Oviaño M, Beceiro A, González-Bello C, Oliver A, Arca-Suárez J, Bou G. Selection of AmpC β-Lactamase variants and Metallo-β-Lactamases leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam resistance during treatment of MDR/XDR Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0206721. | |
| dc.identifier.doi | 10.1128/aac.02067-21 | |
| dc.identifier.issn | 0066-4804 | |
| dc.identifier.uri | https://hdl.handle.net/2183/46347 | |
| dc.language.iso | eng | |
| dc.publisher | American Society of Microbiology | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI18%2F00501/ES/DISEÑO Y DESARROLLO DE UNA VACUNA PARA LA PREVENCION Y ERRADICACION DE LAS INFECCIONES RESPIRATORIAS AGUDAS Y CRONICAS (FIBROSIS QUISTICA) CAUSADAS POR PSEUDOMONAS AERUGINOSA/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F01482/ES/EVALUACION DE NUEVAS ESTRATEGIAS ANTIMICROBIANAS MEDIANTE SILENCIAMIENTO DE ARN VEHICULIZADO EN NANOCAPSULAS E INHIBIDORES ENZIMATICOS/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F01212/ES/DESARROLLO Y EVALUACION DE NUEVAS MOLECULAS ANTIMICROBIANAS DIRIGIDAS A PATOGENOS MULTIRRESISTENTES (INHIBIDORES DE ß-LACTAMASAS Y CONJUGADOS TETRACICLINAS-SIDEROFOROS). ESTUDIO NACIONAL ACINETOBACTER SPP./ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-105512RB-I00/ES/COMBATIENDO LAS BACTERIAS RESISTENTES A LOS ANTIBIOTICOS Y CONTROLANDO SU EVOLUCION IN VIVO MEDIANTE ESTRATEGIAS INNOVADORAS Y NUEVOS TESTS DE DIAGNOSTICO CLINICO/ | |
| dc.relation.uri | https://doi.org/10.1128/aac.02067-21 | |
| dc.rights | Attribution 4.0 International | en |
| dc.rights.accessRights | open access | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Pseudomonas aeruginosa | |
| dc.subject | Antibiotic resistance | |
| dc.subject | Beta-lactamases | |
| dc.subject | Beta-lactams | |
| dc.subject | Cephalosporin | |
| dc.subject | Mechanisms of resistance | |
| dc.title | Selection of AmpC β-Lactamase variants and Metallo-β-Lactamases leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam resistance during treatment of MDR/XDR Pseudomonas aeruginosa infections | |
| dc.type | journal article | |
| dc.type.hasVersion | AM | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea | |
| relation.isAuthorOfPublication.latestForDiscovery | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Ruedas_Selection_2022.pdf
- Size:
- 993.28 KB
- Format:
- Adobe Portable Document Format

